Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
Paolo
Sep 10, 2023, 17:27 |
Insight
Paolo Tarantino: In our latest The Oncologist article led by Edoardo Crimini, we analyze geographical accessibility to NGS-informed trials in Italy
Paolo Tarantino, MD, Clinical research fellow at the Dana-Farber Cancer Institute, shared the following insight…
Sep 2, 2023, 00:32 |
Insight
Paolo Tarantino: The “5 S rules” can help memorize a simple framework to optimally manage ILD.
Paolo Tarantino, MD and researcher at the European Institute of Oncology and clinical research fellow…
Aug 29, 2023, 18:43 |
Blog
Paolo Tarantino: So many changes since last year... one thing, though - one corner, remained the same. Luckily.
Quoting Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, on X/Twitter: "So many changes…
Aug 24, 2023, 18:16 |
Blog
Paolo Tarantino: Retrospective study by Viale et al. on HER2-low breast cancer.
Quoting Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, on Twitter: ''Just out on…
Aug 23, 2023, 23:49 |
Blog
Paolo Tarantino: Interesting pan-cancer evaluation of HER2-low expression out on Annals of Oncology.
Paolo Tarantino, a Research Fellow at the Dana-Farber Cancer Institute, shared the following insights on…
Aug 15, 2023, 09:15 |
Insight
Paolo Tarantino: Delivering chemo via HER2- and Trop2-targeted Antibody-drug conjugates (ADCs) has reshaped the way we treat Metastatic breast cancer (MBC)
Paolo Tarantino, MD, Clinical Research Fellow at Dana-Farber Cancer Institute, stated on Twitter: "Delivering chemo…
Aug 6, 2023, 17:11 |
Blog
Here’s a personal, non-exhaustive selection of highly awaited phase 3 trials that may shape practice within the next year - Paolo Tarantino
With ESMO23 and SABCS23 approaching, we may soon see the results from several potentially practice-changing…
Jul 28, 2023, 08:26 |
Blog
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has the strongest data in support? - Paolo Tarantino
Both T-DXd and SG are approved for patients with HER2-low TNBC. But which one has…
Jul 23, 2023, 16:19 |
Blog
The first oral SERD gets closer to Europe - Paolo Tarantino
Positive CHMP opinion on the marketing authorization of elacestrant for patients with HR+/HER2- MBC with…
Jul 19, 2023, 18:34 |
Insight
In breast oncology there is a pre-TDXd & a post-TDXd era, with the latter still at the dawn - Paolo Tarantino
In breast oncology there is a pre-TDXd & a post-TDXd era, with the latter still…
14
15
16
17
18
All:
264
Posts:
151 - 160
Peyo the Therapy Horse: Comforting Terminally Ill Patients Through Horse Therapy.
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 3
Small Bowel Cancer: Symptoms & Causes, Types, Diagnosis and Treatment
Mikkael A. Sekeres, Candidate for Secretary of ASH
Paolo Tarantino: Top 10 Breast Cancer abstracts from ESMO2024
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube